Aqilion presents Nomination Committee for the 2024 Annual General Meeting

The Nomination Committee for the 2024 Annual General Meeting has been appointed and comprises the following members:

• Christian Ewe, appointed by the shareholder LMK Forward AB

• Linus Wiebe, appointed by the shareholder Fåhraeus Start Up and Growth AB

• Katarina Berggren, appointed by the shareholder Grenspecialisten AB

The members appoint the Chairman among themselves.

The Nomination Committee shall prepare proposals for the 2024 Annual General Meeting

regarding the Chairman of the meeting, election of Board members and Chairman of the Board, the fees to be paid to the Board Chairman and the Board members, remuneration to the auditor and election of the auditor.

The Annual General Meeting of AQILION AB (publ) will be held on Monday June 10, 2024, at 05.00 p.m. (CET) in Helsingborg, Sweden.

For more information, please contact:
Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com

About Aqilion

Aqilion is a Swedish biotech company developing innovative treatments for diseases caused by chronic inflammation and dysfunctional immune reactions.

The company is mainly active in early phases of drug discovery, taking ideas to early clinical development. The goal is to demonstrate the clinical and commercial potential of the medical innovation to attract industrial partners and buyers, who in turn have the capacity to continue clinical development and commercialization.

Aqilion runs its development programs in a partly virtual organization in close collaboration with selected partners with specific expertise in drug development.

AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden. www.aqilion.com

Tags: